Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Satellos Bioscience ( (TSE:MSCL) ) has issued an update.
On February 24, 2026, Toronto-based Satellos Bioscience said it will showcase new clinical and preclinical data for its lead drug SAT-3247 at the Muscular Dystrophy Association Clinical & Scientific Conference in Orlando from March 8–11. The company plans two oral presentations, including results from a completed Phase 1a/b study in healthy volunteers and adults with Duchenne muscular dystrophy, and data on SAT-3247’s impact in a mouse model of facioscapulohumeral muscular dystrophy.
Satellos will also present three posters covering the Phase 1a/b SAT-3247 study, the TRAILHEAD open-label Phase 2 trial in adults with Duchenne muscular dystrophy, and research quantifying reduced regenerative potential in DMD patients aged 7–11. The planned disclosures underscore Satellos’ efforts to position SAT-3247 as a first-in-class, dystrophin-independent therapy in the muscular dystrophy field and may help build clinical and scientific support ahead of further development.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on TSE:MSCL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.
To see Spark’s full report on TSE:MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing small-molecule drugs to restore natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, is an orally administered AAK1 inhibitor being advanced as a potential disease-modifying therapy for Duchenne muscular dystrophy (DMD) and other conditions involving skeletal muscle loss, irrespective of dystrophin status or exon mutation.
Average Trading Volume: 32,756
Technical Sentiment Signal: Buy
Current Market Cap: C$238.8M
Find detailed analytics on MSCL stock on TipRanks’ Stock Analysis page.